Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers-Reference-Cited by-同舟云学术

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers

Published:2020-07-01 Issue:7 Volume:6 Page:1048
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Yu Helena A.¹,Schoenfeld Adam J.¹,Makhnin Alex¹,Kim Rachel¹,Rizvi Hira²,Tsui Dana³,Falcon Christina²,Houck-Loomis Brian³,Meng Fanli³,Yang Julie Li³,Tobi Yosef¹,Heller Glenn⁴,Ahn Linda¹,Hayes Sara A.⁵,Young Robert J.⁵,Arcila Maria E.³,Berger Michael⁶,Chaft Jamie E.¹,Ladanyi Marc⁶,Riely Gregory J.¹,Kris Mark G.¹

Affiliation:

1. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York

2. Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

4. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

6. Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2766465/jamaoncology_yu_2020_oi_200018.pdf

Reference26 articles.

1. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer.;Soria;N Engl J Med,2018

2. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.;Sequist;J Clin Oncol,2013

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation–positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.;Rosell;Lancet Oncol,2012

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.;Maemondo;N Engl J Med,2010

5. LBA5_PR—Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis.;Ramalingam;Ann Oncol,2019

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

2. Osimertinib in Combination with Bevacizumab for EGFR Mutated Recurrent Glioblastoma (GBM): A Case Report;Journal of Neuro and Oncology Research;2024-01-16

3. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

4. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

5. An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment;Heliyon;2024-01